1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

https://doi.org/10.3322/caac.21492

PMid:30207593 

2. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8:11884-94.

PMid:26617944

3. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309-16.

https://doi.org/10.1016/j.oraloncology.2008.06.002

PMid:18804401 

4. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50:627-32.

https://doi.org/10.1016/j.oraloncology.2014.04.003

PMid:24819861 

5. Moskovitz J, Moy J, Ferris RL. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oncol Rep. 2018;20:22.

https://doi.org/10.1007/s11912-018-0654-5

PMid:29502288 PMCid:PMC5835060

6. Li Z, Song W, Rubinstein M, Liu D. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing. J Hematol Oncol. 2018;11:142.

https://doi.org/10.1186/s13045-018-0684-3

PMid:30577797 PMCid:PMC6303854

7. Hartner L. Chemotherapy for Oral Cancer. Dent Clin North Am. 2018;62:87-97.

https://doi.org/10.1016/j.cden.2017.08.006

PMid:29126496 

8. Hill BT, Price LA. Lack of survival advantage in patients with advanced squamous cell carcinomas of the oral cavity receiving neoadjuvant chemotherapy prior to local therapy, despite achieving an initial high clinical complete remission rate. Am J Clin Oncol. 1994;17:1-5.

https://doi.org/10.1097/00000421-199402000-00001

PMid:8310999 

9. Lin JC, Jan JS, Hsu CY, Wong DY. High rate of clinical complete response to weekly outpatient neoadjuvant chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin. Cancer. 1999;85:1430-8.

https://doi.org/10.1002/(SICI)1097-0142(19990401)85:7<1430::AID-CNCR2>3.0.CO;2-I

PMid:10193931

10. Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K, Mouratidou D. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol. 2003;39:380-5.

https://doi.org/10.1016/S1368-8375(02)00141-0

PMid:12676258

11. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689-708.

https://doi.org/10.1677/erc.1.00600

PMid:15613446 

12. Rodríguez-Caballero A, Torres-Lagares D, Robles-García M, Pachón-Ibáñez J, González-Padilla D, Gutiérrez-Pérez JL. Cancer treatment-induced oral mucositis: a critical review. Int J Oral Maxillofac Surg. 2012;41:225-38.

https://doi.org/10.1016/j.ijom.2011.10.011

PMid:22071451 

13. Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014;58:341-9.

https://doi.org/10.1016/j.cden.2013.12.005

PMid:24655526 

14. Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020;39:210.

https://doi.org/10.1186/s13046-020-01715-7

PMid:33028357 PMCid:PMC7542970

15. Kusiak A, Jereczek-Fossa BA, Cichońska D, Alterio D. Oncological-Therapy Related Oral Mucositis as an Interdisciplinary Problem-Literature Review. Int J Environ Res Public Health. 2020;17:2464.

https://doi.org/10.3390/ijerph17072464

PMid:32260309 PMCid:PMC7177874

16. Blakaj A, Bonomi M, Gamez ME, Blakaj DM. Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data. Oral Oncol. 2019;95:29-34.

https://doi.org/10.1016/j.oraloncology.2019.05.013

PMid:31345391 

17. López-Castaño F, Oñate-Sánchez RE, Roldán-Chicano R, Cabrerizo-Merino MC. Measurement of secondary mucositis to oncohematologic treatment by means of different scale. Review. Med Oral Patol Oral Cir Bucal. 2005;10:412-21.

PMid:16264377

18. Çakmak S, Nural N. Incidence of and risk factors for development of oral mucositis in outpatients undergoing cancer chemotherapy. Int J Nurs Pract. 2019;25:e12710.

https://doi.org/10.1111/ijn.12710

PMid:30461128 

19. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.

https://doi.org/10.1186/2046-4053-4-1

PMid:25554246 PMCid:PMC4320440

20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

https://doi.org/10.1371/journal.pmed.1000097

PMid:19621072 PMCid:PMC2707599

21. Ferris RL, Blumenschein GJ, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856-67.

https://doi.org/10.1056/NEJMoa1602252

PMid:27718784 PMCid:PMC5564292

22. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156-67.

https://doi.org/10.1016/S0140-6736(18)31999-8

PMid:30509740

23. Kiyota N, Hasegawa Y, Takahashi S, Yokota T, Yen CJ, Iwae S, et al. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncol. 2017;73:138-46.

https://doi.org/10.1016/j.oraloncology.2017.07.023

PMid:28939066 

24. Tahara M, Muro K, Hasegawa Y, Chung HC, Lin CC, Keam B, et al. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. Cancer Sci. 2018;109:771-6.

https://doi.org/10.1111/cas.13480

PMid:29284202 PMCid:PMC5834807

25. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:3838-45.

https://doi.org/10.1200/JCO.2016.68.1478

PMid:27646946 PMCid:PMC6804896

26. Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153-9.

https://doi.org/10.1038/s41416-018-0131-9

PMid:29955135 PMCid:PMC6048158

27. Harrington KJ, Ferris RL, Blumenschein GJ, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18:1104-15.

https://doi.org/10.1016/S1470-2045(17)30421-7

PMid:28651929